Abstract:Yueyuan Wang, &ast Bo Lv, &ast Kai Fan, Cunjin Su, Delai Xu, Jie Pan Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jie Pan; Delai Xu, Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, People's Republic of China, Email ; Purpose: Parkinson's disease (PD) is a common neurodegenerative disease that severely affects patients' daily lives and places a significant burden on the global economy. There are currently no specific biomarkers for distinguishing between the different stages of PD. Methods: We divided 78 mice into six equal groups, including five model PD groups (W1–W5; based on the PD stage induced by length of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/propofol induction time) and a control group. Then, we used metabolomics technology to detect the serum small-molecule metabolites present in each group. Ultimately, we screened for potential biomarkers using the variable importance in the projection of the orthogonal partial least squares discriminant analysis and the coefficient value of LASSO ordinal logistic regression. Results: We identified 12 potential biomarkers, including dehydroepiandrosterone sulfate, pipecolic acid, N-acetylleucine, 2-aminoadipic acid, L-tyrosine, uric acid, and 5-hydroxyindoleacetaldehyde. Pathway analysis revealed their involvement in amino acid metabolism, caffeine metabolism, steroid hormone biosynthesis, and purine metabolism. Additionally, the receiver operating characteristic curve indicated that a biomarker panel comprising the 12 biomarkers could differentiate between the different PD stages. Conclusion: Different PD stages are characterized by different metabolites. The biomarkers identified in this study are helpful to understand the PD process. Keywords: Parkinson's disease, metabolomics, biomarkers, metabolic disturbances, LC–MS Parkinson's disease (PD), the second most common chronic neurodegenerative disease after Alzheimer's disease, is a multisystem disorder with multiple mechanisms and neurochemical features. It affects 2% of people aged >65 years and 4% of people aged >80 years. 1–3 The number of people with PD is expected to reach 12 million by 2050 4 , and this increased incidence may cause high economic and social burdens. PD is a multifactorial and sporadic disease. Its highly complex pathogenesis has not been fully elucidated and may be related to mitochondrial dysfunction, oxidative stress, and the inflammatory response. 5 The diagnostic criteria for PD include the recognition of specific clinical symptoms that are already evident in the patient, usually several years after the neurodegenerative process has occurred. Additionally, even if the diagnostic criteria are correctly applied, the rate of PD misdiagnosis is high for some nonspecific clinical symptoms. Although positron emission tomography and single-photon emission computed tomography imaging are highly sensitive and can be used for imaging diagnosis of PD, they are not specific to PD, are costly, and carry the risk of radiation exposure. Therefore, it is crucial to investigate the mechanisms and evolution of PD and to search for PD biomarkers. 6 Metabolomics is the science of quantitatively measuring the composition of all metabolites of a biological system (cell models, tissues, organs, or whole organisms), usually small-molecule metabolites with relative molecular masses <1000, as well as dynamic alterations in these metabolites in response to internal and external stimuli. 7 This rapidly developing emerging discipline follows the advent of genomics, transcriptomics, and proteomics and has been widely used in various fields, such as nutrition, toxicology, and disease diagnosis. 8 Improvements in high-resolution mass spectrometry technology have led to the increasingly extensive application of metabolomics technology in clinical medicine, especially in screening for disease biomarkers and intrinsic regulatory mechanisms. Metabolites play active regulatory roles in systems biology, and metabolomics tools provide a direct functional readout of an organism's physiological state, which is difficult to obtain using other histological methods. Thus, the resultant metabolic profile is a complete description of the organism's phenotype. 9 In recent years, the development of analytical and bioinformatic tools has resulted in the exponential growth of metabolomics research. Further studies, such as the functional analysis of metabolites, may lead to the discovery of relevant bioinformation, such as protei -Abstract Truncated-

Metabolomic profiling reveals altered phenylalanine metabolism in Parkinson's disease in an Egyptian cohort

Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease.

Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism

Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry

Metabolomics Unveils Disrupted Pathways in Parkinson's Disease: Toward Biomarker-Based Diagnosis

Nontargeted metabolomics reveals sequential changes in amino acid and ferroptosis‐related metabolism in Parkinson's disease

Identification of gut metabolites associated with Parkinson's disease using bioinformatic analyses

A metabolomics study in aqueous humor discloses altered arginine metabolism in Parkinson's disease

Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease

The role of dopaminergic medication, lipid, and endocannabinoid pathway alterations in idiopathic and -mediated Parkinson’s disease – a large-scale targeted metabolomics study

Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson’s disease

Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra

Metabolic Disturbances in a Mouse Model of MPTP/Probenecid-Induced Parkinson's Disease: Evaluation Using Liquid Chromatography-Mass Spectrometry

Metabolomics of Blood Reveals Age-Dependent Pathways in Parkinson’s Disease

Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome

Alterations in Blood Methylome as Potential Epigenetic Biomarker in Sporadic Parkinson's Disease

Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease

Advances of Mechanisms-Related Metabolomics in Parkinson’s Disease

Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome-Wide Association Study

Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status

Omics data integration suggests a potential idiopathic Parkinson's disease signature